Glucose Viaflo Baxter

Glucose Viaflo Baxter is an intravenous solution that contains glucose monohydrate as its sole active ingredient. Formulated as a sterile, isotonic fluid for parenteral administration, the product is supplied in a ready‑to‑use container without a specified concentration in the label excerpt. It is classified as an excipient carbohydrate solution and is marketed in the European Union under a prescription‑only status and intended for hospital use.

Glucose Viaflo Baxter is used in clinical settings where rapid provision of carbohydrate energy and fluid balance is required.

- Treatment of documented hypoglycemia in patients unable to receive oral glucose. - As an energy source during parenteral nutrition for patients who are nil per os or have limited enteral intake. - Fluid and electrolyte replenishment in perioperative or trauma patients needing isotonic volume expansion. - Dilution and compatibility agent for certain intravenous medications that require a carbohydrate carrier. - Support of metabolic demands during prolonged fasting or critical illness.

The safety profile of Glucose Viaflo Baxter reflects the expected pharmacologic actions of an intravenous glucose solution, with most adverse events being mild and related to the infusion itself.

Common: - Transient hyperglycemia when administered in excess. - Local irritation or pain at the infusion site. - Mild electrolyte shifts, particularly sodium or potassium changes. - Nausea or vomiting if the solution is infused rapidly. - Mild headache reported during rapid infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypersensitivity reactions, including rash, urticaria, or anaphylaxis. - Fluid overload causing pulmonary edema in patients with compromised cardiac function. - Hyperosmolar hyperglycemic state in patients with uncontrolled diabetes. - Metabolic acidosis in severe hyperglycemia cases.

When using Glucose Viaflo Baxter, clinicians should assess patient-specific factors and monitor parameters to minimize risks associated with intravenous carbohydrate administration.

- Verify blood glucose levels before and after infusion to avoid extreme hyper- or hypoglycemia. - Adjust infusion rate in patients with renal or hepatic impairment to prevent accumulation. - Monitor fluid balance closely in patients with heart failure or pulmonary edema risk. - Avoid concurrent administration with high‑dose potassium solutions unless compatibility is confirmed. - Ensure aseptic technique to reduce the risk of catheter‑related infections.

Glucose Viaflo Baxter may interact with other intravenous agents or systemic medications, influencing glucose homeostasis, electrolyte balance, or solution compatibility.

Avoid: - Co‑administration with high‑concentration dextrose solutions that could cause hyperosmolarity. - Simultaneous infusion with calcium-containing solutions without proper compatibility testing.

Use with caution: - Concurrent use of insulin or oral hypoglycemics, which may increase risk of hypoglycemia. - Administration alongside potassium chloride, as rapid glucose infusion can shift potassium intracellularly. - Use with diuretics that affect fluid and electrolyte status, requiring close monitoring. - Combination with beta‑adrenergic agonists, which can raise blood glucose levels.